A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors
Roxanne Toivanen, Mark Frydenberg, Declan Murphy, John Pedersen, Andrew Ryan, David Pook, David M Berman, Renea A Taylor, Gail P Risbridger
SCIENCE TRANSLATIONAL MEDICINE | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2013
A lack of clinically relevant experimental models of human prostate cancer hampers evaluation of potential therapeutic agents. Currently, androgen deprivation therapy is the gold standard treatment for advanced prostate cancer, but inevitably, a subpopulation of cancer cells survives and repopulates the tumor. Tumor cells that survive androgen withdrawal are critical therapeutic targets for more effective treatments, but current model systems cannot determine when they arise in disease progression and are unable to recapitulate variable patient response to treatment. A model system was developed in which stromal-supported xenografts from multiple patients with early-stage localized disease c..View full abstract
Awarded by National Health and Medical Research Council
This research was funded by the National Health and Medical Research Council (# 606492 and # 43796), Victorian Cancer Agency (CAPTIV: Prostate Cancer Collaborative Grant), Peter and Lyndy White Foundation, and Prostate Cancer Foundation of Australia (Movember Young Investigator Grant to R.A.T.).